CMS Drafting PET Scan NCD, To Cover Alzheimer’s MRIs

Alongside its plan to gather observational data on potential adverse effects linked to the newly approved Alzheimer’s drug Leqembi, CMS will also soon propose a national coverage determination loosening current PET scan restrictions and will cover reasonable and necessary MRIs, a CMS spokesperson told Inside Health Policy Friday (July 7). Currently, the spokesperson said, Medicare covers one positron emission tomography (PET) scan per lifetime to detect amyloid beta plaque, but the agency is currently reconsidering that and intends to...